Abstract

Pharmaceutical manufacturing is undergoing a paradigm shift—from traditional batch processes toward continuous and hybrid systems. This transition is driven by the need for greater process control, reduced variability, faster throughput, and enhanced product quality, especially in sterile and regulated environments. This article explores key engineering strategies that support this transformation, including hybrid reactor design, clean-in-place optimization, automation architecture, and modular scalability. Drawing from practical implementation in formulation and fill/finish platforms, the author presents actionable insights to improve system reliability, cleanability, and compliance in modern pharmaceutical settings. The article also contrasts batch and continuous manufacturing paradigms, highlighting the advantages of continuous systems while acknowledging implementation challenges.

Peer-Reviewed

Submitted: June 27, 2025

Accepted: January 14, 2026

Pharmaceutical manufacturing has traditionally operated under a batch processing model, a methodology rooted in simplicity, traceability, and discrete control. In a batch setup, raw materials are introduced, processed through predefined steps, and output as a finished lot—after which the system is cleaned, reset, and prepared for the next run. While this method offers clear demarcation between batches and straightforward quality tracking, it is inherently limited in speed, flexibility, and responsiveness to demand fluctuations.

Key benefits of batch manufacturinginclude flexibility for small-scale production and multi-product facilities, lower risk of large-scale waste in the event of contamination or deviation, simpler troubleshooting due to natural process pauses, and lower upfront capital investment compared with full continuous manufacturing (CM) platform build-outs.1

Batch manufacturing also presents several well-known challenges: scalability bottlenecks, extended lead times due to cleaning/reconfiguration, higher manual intervention, and under-utilized capacity between operations.

In contrast, CM integrates processing into a steady-state operation: raw materials are continuously fed and transformed into product without interruption. This paradigm—mature in petrochemical/food industries—is increasingly adapted for oral solid dose, sterile injectables, and biologics.2-3 A comparative overview of batch, hybrid, and continuous manufacturing approaches is shown in Figure 1.

Key advantages of CM, as supported by regulatory guidance and published case studies,1-4 include reduced cycle times via elimination of inter-unit downtime and queueing. Regulators and case studies report substantial timeline compression when steady state is achieved.2-3 Increased productivity/throughput per footprint is achieved owing to smaller, intensified equipment operating continuously, as demonstrated in published continuous manufacturing case studies.2,4 Improved product quality is enabled through process analytical technology (PAT)-enabled real-time monitoring and control strategies aligned with the FDA’s PAT framework.1,3 Sustainability gains are realized through lower water, energy, and cleaning agent use due to fewer stop-starts and optimized clean-in-place (CIP) operations, as reported in industry case studies.2

There are also risks and challenges associated with CM, including:

• System-wide interruptions if a single component or sensor fails (akin to a train halting if one carriage breaks).
• Potentially larger in-process material at risk during deviations/contamination events, requiring rapid detection and diversion strategies.3
• Higher initial validation/automation complexity, training requirements, and capital expenditure (CAPEX) to implement integrated CM lines.3,4
• Regulatory acceptance challenges, such as demonstrating that CM can produce the equivalent product quality profile (PQP) as batch processes, while addressing evolving guidelines in some markets.1,3
• Batch numbering and recall complexity; defining lot boundaries and managing targeted recalls in a continuous process require tailored control strategies.
• Sensor dependency risk. CM relies heavily on PAT and the continuous functionality of critical sensors (e.g., pH probes). A single sensor failure can compromise process control and quality, necessitating rapid diversion or shutdown.
• Sensor location determination; identifying optimal PAT sensor placement is a time-consuming and resource-intensive exercise during system design, often requiring iterative testing and validation.

A detailed comparison of batch and continuous manufacturing is summarized in Table I.

Applications of Continuous Manufacturing

Continuous manufacturing principles are being increasingly applied to both small‑molecule and biologic pharmaceutical workflows, streamlining operations from synthesis to final formulation.

Drug product formulation. For both small molecules and biologics, final drug product formulation involves combining API or biologic with excipients to ensure safe, stable, and effective delivery to the patient. This primarily includes liquid dosage forms such as sterile injectables, suspensions, and biologic delivery systems. Continuous manufacturing supports these processes through precise component dosing, efficient mixing under controlled conditions, and real‑time monitoring of critical quality attributes (CQAs), improving consistency and reducing variability across batches.

Batch is well‑suited for small/variable demand programs and development lots, with natural hold points that simplify in‑process investigations and formulation adjustments between runs.4 It enables tight control of mixing, pH, and temperature with PAT for CQAs (supports real-time release testing [RTRT] strategies), reducing variation and shortening time to disposition.1,3 For high‑volume SKUs, steady‑state operation can compress cycle time and raise throughput per footprint.2-4

Vaccine and biologic formulation. Biologics and vaccines often include sensitive molecules, such as proteins, messenger RNA (mRNA), or viral vectors, which require carefully controlled conditions to maintain stability and efficacy. Formulation steps typically involve blending with stabilizers, adjuvants, or preservatives in aseptic environments. Continuous systems offer superior control over temperature, shear, and pH, reducing degradation risks and ensuring consistent product quality—particularly vital for parenteral administration.

CM offers segmented unit operations (eg, hold tanks with environmental control) that can be advantageous for stability testing, viral safety steps, or bridging comparability assessments between stages.4

Inline control of shear, residence time, and temperature helps preserve labile modalities (eg, proteins, mRNA) and supports consistent CQAs across long campaigns2; however, campaigns require robust alarm handling, redundancy, and diversion strategies to mitigate train‑wide upsets.3

API manufacturing for small molecules. While APIs are not considered formulations, their quality directly impacts downstream formulation. Continuous API synthesis—particularly using flow chemistry platforms—enables tighter control over reaction kinetics, improved impurity profiles, safer handling of hazardous materials, and faster transition from development to commercial scale. This is especially valuable for high‑potency or fast‑track compounds requiring integrated development timelines.

Batches have a familiar infrastructure and mature regulatory expectations; flexible for multi‑step chemistries that benefit from isolation/purification between steps or where thermal runaways must be tightly bounded in discrete charges. 4

Flow reactors allow enhanced heat/mass transfer, in‑situ quenching, and hazard containment, often improving selectivity and impurity control; integration with PAT accelerates development and tech transfer.1,2

A risk–benefit comparison across different pharmaceutical modalities is summarized in Table II.

Regulatory context (applies to all three areas). The FDA and other agencies have explicitly encouraged the use of PAT and advanced manufacturing as enablers of consistent quality and potential real‑time release, with growing precedents for CM submissions. 1,3

The Engineering Challenge

The goal was to design a process that could:

• Consistently mix multiple components
• Precisely control pH in real time
• Achieve sterile product in the final collection vessel

• Operate within a cleanroom environment with validated CIP capability
• Handle pressure-sensitive processing steps safely and reproducibly

This type of process architecture is increasingly common in modern pharmaceutical facilities.

Reactor System Selection and Hybridization

Conventional CSTR cascades. The continuous stirred-tank reactor (CSTR) cascade is a workhorse configuration widely used in buffer preparation and formulation. In a cascade, multiple tanks operate in series, each performing part of the mixing or conditioning process. This provides excellent residence time control and process staging flexibility.

CSTR cascades allow for segmented pH control, modular dosing, and temperature staging. However, they also increase cleaning requirements, utility consumption, and equipment footprint. Each tank requires separate instrumentation, spray coverage, and control logic. Changeovers are time-consuming, and system validation requires thorough documentation across each unit operation.

Plug flow–CSTR systems. A more modern approach involves combining a plug flow reactor (PFR)—typically a static mixer or coiled flow segment—with a single CSTR for final conditioning. This hybrid system delivers rapid dilution or component blending upstream, followed by tight pH or temperature control downstream.

In practice, buffer salts or acid/base components enter the PFR and undergo rapid mixing before reaching a stirred vessel. The CSTR handles delicate process steps like pH trimming or thermal stabilization. Because the PFR section has no moving parts and fewer hold-up areas, cleaning and validation are faster. The overall system footprint is smaller, and fewer valves or instruments are required.

Hybrid systems excel when fast blending and precise conditioning are both needed, such as in sterile formulation of biologics or buffered excipient systems.

Engineering insights. While multi-stage CSTRs offer fine control, a simpler hybrid system can often deliver equivalent product quality with lower operational burden. Simplified system architectures can reduce equipment cost, cleaning time, and risk of process deviations.

Clean-in-Place (CIP) Design Considerations

Spray coverage and geometry. Effective spray systems reach all product contact surfaces with validated coverage. Rotating spray devices are often used in large vessels, while static spray balls work well in smaller tanks. For piping, internal surface roughness must be minimized, and slope must support full drainability. Riboflavin dye tests, visualized under UV light, confirm that cleaning agents reach all surfaces.

CIP cycle structure. A typical automated CIP sequence includes:

• Initial rinse with warm purified water
• Alkaline detergent wash
• Intermediate rinse
• Optional acid rinse for scale removal
• Final rinse to meet conductivity targets

Each step is monitored using flow, temperature, and conductivity sensors. Logs from these sensors form part of the batch record and are critical for validation.

From a batch perspective, vessel-focused cleaning with full process stoppage allows for physical inspection post-cleaning. CIP cycles can be optimized per batch without affecting production schedules.4

From a continuous perspective, CIP in CM must often occur inline or in partial shutdowns; validation must demonstrate full coverage in piping, static mixers, and process skids under operational constraints.1,3 Inline riboflavin coverage testing and PAT verification of rinse endpoints are often required mid-campaign1.

Material compatibility. Equipment must be constructed from materials compatible with CIP chemistry. Elastomers, gaskets, and pump seals should resist degradation from repeated exposure to alkaline and acidic agents. Smooth transitions between fittings, proper weld quality, and reduced dead legs ensure microbial control and reduce cleaning time.

From a batch perspective, shorter cumulative exposure of elastomers and gaskets to cleaning agents; easier to schedule replacement during downtime.4

From a continuous perspective, extended campaigns require materials that withstand prolonged exposure to cleaning and product contact without degradation.1,3 CM changeovers demand compatibility across a wider operational envelope.

Automation and Real-Time Control Architecture

Closed-loop control systems. Sensors measure parameters like pH, conductivity, temperature, flow rate, and pressure. These values feed into closed-loop algorithms that control the following:

• Acid/base dosing for pH adjustment
• Cooling/heating circuits for thermal regulation
• Pump speed and valve positions for flow and level control

Alarms and interlocks prevent unsafe or off-spec operation. For instance, a drop in flow below a threshold may trigger a pump shutdown, while a pressure spike might open a bypass loop.

Alarm management. Multi-tiered alarms ensure timely intervention of the following:

• Level 1: Operator notification, no action required
• Level 2: Intervention required, HMI alert and log
• Level 3: Critical fault, process halt, and supervisor escalation

Each alarm triggers a timestamped entry in the system log, preserving data integrity and simplifying troubleshooting.

Batch data logging. Modern systems include integrated data historians. Each batch run stores profiles of sensor readings, dosing rates, CIP cycle times, and alarm histories. These data support deviation analysis, root-cause investigations, and continuous improvement programs.

From a batch perspective, alarms can be acknowledged and corrected before resuming; downtime for intervention is inherent to the mode of operation.4

From a continuous perspective, alarms require immediate automated or operator action to prevent loss of large in-process volumes.3 Multi-tiered alarms in CM are critical to avoid complete train stoppage, and redundancy in critical sensors (eg, pH probes) is strongly recommended.3

Pressure-Sensitive Operations and Filtration Integrity

In sterile processing, particularly during final filtration, pressure control is critical. Filters used in aseptic applications are validated for integrity and pressure limits.

Pressure sensors are positioned upstream and downstream of the filter housing. The difference in pressure (ΔP) indicates filter loading or fouling. When ΔP exceeds a set point, the system may reduce flow or divert to a parallel filtration path.

Automated filter integrity testing is performed pre- and post-use, typically via bubble point or pressure hold methods. Results are captured automatically and included in batch reports.

Valves, pumps, and tubing are configured to minimize pulsation, backpressure, and exposure to sudden changes in flow—safeguarding both product and equipment.

Safe flow control integration. In sterile pharmaceutical systems, particularly those involving filtration or biologics, maintaining precise pressure profiles is essential to ensure both product integrity and equipment longevity. Many processes use pressure-sensitive membranes or fragile biologic materials that can be compromised by overpressure, pulsation, or sudden flow changes.

To mitigate these risks, the system incorporated safety-driven flow control mechanisms. One critical addition was the use of auto-cutoff flow sensors, such as pressure-monitoring and auto-cutoff flow sensors integrated with peristaltic pump platforms. These devices are not only economically viable but also enhance operational safety by halting flow automatically when downstream pressure exceeds a preset limit. This design effectively prevents membrane damage, avoids unintentional over-pressurization, and reduces the likelihood of operator error during operation or transition phases.

The system also featured continuous pressure monitoring, with programmable interlocks that trigger alarms or system shutdowns if unsafe conditions are detected. This added layer of protection ensured that deviations were identified and addressed rapidly, preventing escalation into batch failures or equipment downtime.

From a batch perspective, flow control disruptions affect only the current lot; failed pumps or sensors can be isolated without impacting other lots.4

From a continuous perspective, a single failure can halt the process; therefore, redundant flow control, bypass loops, and predictive maintenance become more critical.3

Sterile system design. A typical sterile formulation platform combines hybrid mixing, automated pH control, in-line concentration monitoring, and sterile filtration in a closed-loop configuration. The system is designed for aseptic conditions, minimizing manual handling and maximizing process reliability.

The formulation sequence is as follows:

1. Diluent and buffer preparation. Diluent water and buffers are blended in the PFR, achieving rapid initial mixing.
2. Excipient addition. Preservatives and stabilizers are dosed through controlled feed lines into the CSTR.
3. API introduction. Active ingredient concentrate is added slowly, with low-shear mixing to preserve structure.
4. Conditioning. The solution is gently stirred and cooled, with real-time pH, conductivity, and concentration checks.
5. Filtration. Sterile-grade filtration is applied, with integrity testing before and after the batch.
6. Transfer to fill line. Final product is transferred through closed tubing to the fill/finish suite, minimizing contamination risk.

All contact surfaces are validated for CIP and SIP, and all steps are monitored via PLC with operator oversight.

Scalability and System Flexibility

Equipment sizing and modularity. Engineered systems must scale without compromising performance. Modular process skids and hybrid reactor setups allow flexible adaptation from lab-scale to pilot or full-scale manufacturing.

Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system architecture remain consistent. This allows fast validation and reduced engineering workload. Modular I/O design enables easy addition of new sensors or dosing lines.

Multi-product adaptability. System recipes can be switched quickly via the PLC interface. Recipes control feed composition, dosing volumes, temperature setpoints, and filtration durations. Because CIP routines are automated, changeovers between products are rapid, supporting multi-product facilities.

Defining System Performance Criteria

To ensure quality and efficiency, system performance is measured using a series of quantifiable metrics, such as:

• Yield. Material loss is minimized by reducing hold-up volumes and optimizing filtration steps.
• Cycle time. Time from formulation start to CIP completion is tracked and reduced through automation.
• Cleaning efficiency. Final rinse conductivity, absence of visible residue, and CIP cycle reproducibility are verified.
• Batch reproducibility. Sensor logs confirm that every batch meets specification ranges.
• Alarm response. Operator responsiveness to system deviations is monitored and reviewed for improvement.

Performance benchmarks are reviewed periodically to guide operational upgrades and training.

Safety and environmental controls. Safety is a cornerstone of pharmaceutical operations. In addition to GMP requirements, equipment is designed to prevent operator injury and minimize environmental impact.

Key features include the following:

• Electrical enclosures rated for cleanroom use
• Interlocked access panels and emergency stop controls
• Ergonomic layout to reduce manual strain
• Ventilation and exhaust management for chemical agents
• Low-waste CIP design, minimizing water and detergent consumption

Some facilities incorporate reuse loops or capture tanks to recycle non-contaminated cleaning fluids, aligning process operations with sustainability initiatives.

Operational Best Practices

Teams that maintain high-performing formulation systems typically follow a set of disciplined practices:

• Pre-run checks: All sensors, connections, and valves are verified before initiating a batch.
• Recipe control: Operators follow locked recipes, with deviations requiring supervisor override.
• Inline monitoring: Real-time readings guide adjustments without sampling, preserving sterility.
• Post-run review: After each batch, data logs are reviewed to identify trends or anomalies.
• Preventive maintenance: Pumps, valves, and sensors are serviced based on usage hours or calendar intervals, not just failure.

A culture of continuous improvement helps teams move from reactive maintenance to proactive optimization.

Conclusion

Engineering pharmaceutical systems that deliver quality, reliability, and operational efficiency requires a deliberate integration of reactor design, automation, cleanability, and safety. The examples shared here—centered around hybrid reactors, continuous manufacturing, CIP design, and closed-loop control—demonstrate how modern engineering practice aligns with evolving manufacturing needs.

While continuous manufacturing offers quantifiable gains in cycle time, throughput, and process consistency 2–4, it also presents unique risks, such as system-wide stoppages and higher in-process material exposure during deviations.3 Batch manufacturing remains advantageous in contexts requiring smaller lot sizes, high product variability, or extended stability testing between process stages.4

Selecting between batch, continuous, or hybrid approaches should be a risk-based engineering decision informed by the following:

• Anticipated production volume and demand variability
• Product stability and handling requirements
• Facility infrastructure and available capital investment
• Regulatory expectations and operational readiness. 1,3,4

A decision framework for selecting batch, continuous, or hybrid manufacturing approaches is presented in Figure 2.

The future of pharmaceutical manufacturing will likely be hybrid, leveraging continuous processing where efficiency and consistency are critical, while retaining batch capabilities for flexibility, development, and niche product lines. Aligning technology choice with product and market requirements—and grounding those choices in robust data—will ensure both compliance and competitive performance in a global market.

Glossary of Terms and Abbreviations

• RTRT — Real-Time Release Testing: Analytical approach enabling product release based on real-time process data rather than end-product testing.
• PAT — Process Analytical Technology: Systems for designing, analyzing, and controlling manufacturing processes through timely measurements of critical quality and process parameters.
• CQA — Critical Quality Attribute: A physical, chemical, biological, or microbiological property or characteristic that must be within predefined limits to ensure product quality.
• CPP — Critical Process Parameter: A process variable whose variability impacts a CQA and therefore should be monitored or controlled.
• PQP — Product Quality Profile: The predefined set of quality characteristics that a product must possess to meet its intended safety and efficacy requirements.
• CIP — Clean-in-Place: Automated cleaning of process equipment without disassembly.
• SIP — Sterilize-in-Place: Automated sterilization of process equipment without disassembly.

References

1. FDA. Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. 2004.

2. Lee SL, O'Connor TF, Yang X, et al. Modernizing Pharmaceutical Manufacturing: From Batch to Continuous Production. J Pharm Innov. 2015;10(3):191–199.

3. Nasr MM, Krumme M, Lee SL, et al. Regulatory Advancements in Continuous Manufacturing. J Pharm Sci. 2017;106(11):3199–3205.

4. Allmendinger A, Fischer S. Continuous Manufacturing of Biopharmaceuticals. Current Opinion in Biotechnology. 2021;71:172–180.

Disclosure

This article is based on the author’s professional experience and does not contain any confidential, proprietary, or IP-restricted content. The author affirms that the material complies with all relevant non-disclosure agreements (NDAs) and intellectual property (IP) policies and has not been submitted or published elsewhere. This manuscript is based entirely on publicly known engineering strategies and the author's professional experience. It does not include proprietary or confidential information related to any employer or client.

About the Author

Akanksha Prasad, M.S.is a Senior Chemical Engineering Scientist with over nine years of experience spanning the biopharmaceutical, pharmaceutical, and specialty chemical sectors. She currently leads technology transfer and experimental design initiatives in advanced manufacturing. Her previous work includes roles in vaccine development, process optimization, and upstream/downstream process scale-up across both biologics and small molecule platforms. Holds a Master of Science in Chemical Engineering with a specialization in BioPharma from the Illinois Institute of Technology, Chicago, and a Bachelor of Technology in Chemical Engineering from Bharati Vidyapeeth College of Engineering, Pune. Her technical expertise includes simulation, PAT tools, AKTA systems, DOE, GMP compliance, technology transfer, and scale-up strategies.